Silver Spur Therapeutics
- Biotech or pharma, therapeutic R&D
Our company is a USC spinout focused on the development of targeted nanomedicine therapies. We currently have a pipeline of preclinical-stage assets addressing Autosomal Dominant Polycystic Kidney Disease (ADPKD), Renal Cell Carcinoma, and Atherosclerosis. Our novel platform has demonstrated high efficacy and a strong safety profile in multiple animal studies, positioning us well for translational development. These early results underscore the potential of our nanomedicine platform to transform the treatment landscape across key renal and cardiovascular indications.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}